Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.

@article{Ferrajoli2008LenalidomideIC,
  title={Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.},
  author={Alessandra Ferrajoli and B N Lee and Ellen J. Schlette and Susan O'brien and Hui Gao and Sijin Wen and William G Wierda and Zeev Estrov and Stefan H Faderl and Evan N. Cohen and Changping Li and James M. Reuben and Michael J Keating},
  journal={Blood},
  year={2008},
  volume={111 11},
  pages={5291-7}
}
This study investigated the activity of lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Lenalidomide was given at 10 mg daily with dose escalation up to 25 mg daily. Three patients (7%) achieved a complete response (CR), one a nodular partial remission, and 10 patients a partial remission (PR), for an overall response (OR) rate of 32%. Treatment with lenalidomide was associated with an OR rate of 31% in patients with 11q or 17p deletion, of 24% in patients… CONTINUE READING
Highly Influential
This paper has highly influenced 16 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS